Boltz PBC launched out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta to commercialize an open-science AI stack for molecular structure prediction and therapeutic design. The founders—MIT researchers behind Boltz‑1 and subsequent models—plan Boltz Lab and agent tools for binding affinity and multi‑modality therapeutic design. Boltz aims to make high‑accuracy structure and affinity predictors broadly accessible to academic and startup researchers rather than building a single proprietary drug portfolio, positioning itself as an infrastructure play in AI‑driven discovery.